vs

Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and VORNADO REALTY TRUST (VNO). Click either name above to swap in a different company.

Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $453.7M, roughly 1.1× VORNADO REALTY TRUST). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs 1.1%, a 5.7% gap on every dollar of revenue. On growth, VORNADO REALTY TRUST posted the faster year-over-year revenue change (-0.9% vs -1.7%). Over the past eight quarters, VORNADO REALTY TRUST's revenue compounded faster (2.0% CAGR vs -0.1%).

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

Vornado Realty Trust is a real estate investment trust formed in Maryland in 1982, with its primary office in New York City. The company invests in office buildings and street retail in Manhattan.

MD vs VNO — Head-to-Head

Bigger by revenue
MD
MD
1.1× larger
MD
$493.8M
$453.7M
VNO
Growing faster (revenue YoY)
VNO
VNO
+0.8% gap
VNO
-0.9%
-1.7%
MD
Higher net margin
MD
MD
5.7% more per $
MD
6.8%
1.1%
VNO
Faster 2-yr revenue CAGR
VNO
VNO
Annualised
VNO
2.0%
-0.1%
MD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MD
MD
VNO
VNO
Revenue
$493.8M
$453.7M
Net Profit
$33.7M
$4.9M
Gross Margin
Operating Margin
9.9%
2.8%
Net Margin
6.8%
1.1%
Revenue YoY
-1.7%
-0.9%
Net Profit YoY
10.5%
-14.7%
EPS (diluted)
$0.40
$0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MD
MD
VNO
VNO
Q4 25
$493.8M
$453.7M
Q3 25
$492.9M
$453.7M
Q2 25
$468.8M
$441.4M
Q1 25
$458.4M
$461.6M
Q4 24
$502.4M
$457.8M
Q3 24
$511.2M
$443.3M
Q2 24
$504.3M
$450.3M
Q1 24
$495.1M
$436.4M
Net Profit
MD
MD
VNO
VNO
Q4 25
$33.7M
$4.9M
Q3 25
$71.7M
$27.1M
Q2 25
$39.3M
$759.3M
Q1 25
$20.7M
$102.4M
Q4 24
$30.5M
$5.8M
Q3 24
$19.4M
$-3.6M
Q2 24
$-153.0M
$50.8M
Q1 24
$4.0M
$6.5M
Operating Margin
MD
MD
VNO
VNO
Q4 25
9.9%
2.8%
Q3 25
13.8%
3.0%
Q2 25
12.8%
Q1 25
7.0%
23.2%
Q4 24
7.8%
2.5%
Q3 24
6.6%
-3.3%
Q2 24
-31.3%
10.1%
Q1 24
3.2%
0.1%
Net Margin
MD
MD
VNO
VNO
Q4 25
6.8%
1.1%
Q3 25
14.5%
6.0%
Q2 25
8.4%
172.0%
Q1 25
4.5%
22.2%
Q4 24
6.1%
1.3%
Q3 24
3.8%
-0.8%
Q2 24
-30.3%
11.3%
Q1 24
0.8%
1.5%
EPS (diluted)
MD
MD
VNO
VNO
Q4 25
$0.40
$0.01
Q3 25
$0.84
$0.06
Q2 25
$0.46
$3.70
Q1 25
$0.24
$0.43
Q4 24
$0.37
$0.01
Q3 24
$0.23
$-0.10
Q2 24
$-1.84
$0.18
Q1 24
$0.05
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MD
MD
VNO
VNO
Cash + ST InvestmentsLiquidity on hand
$375.2M
$840.9M
Total DebtLower is stronger
$570.5M
$2.3B
Stockholders' EquityBook value
$865.9M
$6.0B
Total Assets
$2.2B
$15.5B
Debt / EquityLower = less leverage
0.66×
0.38×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MD
MD
VNO
VNO
Q4 25
$375.2M
$840.9M
Q3 25
$340.1M
$1.0B
Q2 25
$224.7M
$1.2B
Q1 25
$99.0M
$568.9M
Q4 24
$229.9M
$733.9M
Q3 24
$103.8M
$783.6M
Q2 24
$19.4M
$872.6M
Q1 24
$8.0M
$892.7M
Total Debt
MD
MD
VNO
VNO
Q4 25
$570.5M
$2.3B
Q3 25
$577.2M
$2.3B
Q2 25
$583.9M
$2.1B
Q1 25
$590.5M
$2.1B
Q4 24
$597.1M
$2.6B
Q3 24
$2.6B
Q2 24
$2.6B
Q1 24
$2.6B
Stockholders' Equity
MD
MD
VNO
VNO
Q4 25
$865.9M
$6.0B
Q3 25
$890.7M
$6.1B
Q2 25
$833.8M
$6.1B
Q1 25
$789.2M
$5.3B
Q4 24
$764.9M
$5.2B
Q3 24
$732.5M
$5.3B
Q2 24
$706.5M
$5.6B
Q1 24
$856.2M
$5.5B
Total Assets
MD
MD
VNO
VNO
Q4 25
$2.2B
$15.5B
Q3 25
$2.2B
$15.7B
Q2 25
$2.1B
$15.6B
Q1 25
$2.0B
$15.6B
Q4 24
$2.2B
$16.0B
Q3 24
$2.1B
$16.1B
Q2 24
$2.0B
$16.2B
Q1 24
$2.2B
$16.2B
Debt / Equity
MD
MD
VNO
VNO
Q4 25
0.66×
0.38×
Q3 25
0.65×
0.37×
Q2 25
0.70×
0.35×
Q1 25
0.75×
0.40×
Q4 24
0.78×
0.50×
Q3 24
0.49×
Q2 24
0.46×
Q1 24
0.46×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MD
MD
VNO
VNO
Operating Cash FlowLast quarter
$114.1M
$1.3B
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.39×
256.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MD
MD
VNO
VNO
Q4 25
$114.1M
$1.3B
Q3 25
$137.3M
$33.2M
Q2 25
$137.2M
$1.0B
Q1 25
$-117.5M
$52.0M
Q4 24
$133.0M
$537.7M
Q3 24
$91.8M
$105.4M
Q2 24
$107.0M
$194.7M
Q1 24
$-125.2M
$31.5M
Cash Conversion
MD
MD
VNO
VNO
Q4 25
3.39×
256.08×
Q3 25
1.91×
1.22×
Q2 25
3.49×
1.35×
Q1 25
-5.66×
0.51×
Q4 24
4.36×
93.39×
Q3 24
4.72×
Q2 24
3.83×
Q1 24
-31.03×
4.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

VNO
VNO

New York Segment$374.8M83%
Building Maintenance Service$41.2M9%
Other$27.7M6%
Tenant Services$11.1M2%
Management And Leasing Fees$2.6M1%

Related Comparisons